HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia.

Abstract
In order to explore the prognostic value of CD2, CD4, and human leucocyte antigen-DR (HLA-DR) expression and Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in leukemia cells in the bone marrow of patients with acute promyelocytic leukemia (APL), we retrospectively collected and analyzed the immunophenotype, molecular features and clinical characteristics of 219 newly diagnosed adult patients with APL in Henan Provincial People's Hospital from January 2010 to December 2019. It turned out that the relapse rates of patients with CD2, CD4, or HLA-DR expression and the early mortality rates of patients with CD2 expression, HLA-DR expression, or FLT3-ITD mutation were higher than those of their counterparts. Moreover, reduced overall survival was found for patients who showed CD2 expression, HLA-DR expression or FLT3-ITD mutation. Therefore, CD2 expression, HLA-DR expression and FLT3-ITD mutation were adverse prognostic factors in adults with APL.
AuthorsLu Nie, Rongjun Ma, Xiaoli Yuan, Li Jiang, Shiwei Yang, Hui Xu, Xiaoyin Liu, Yuanbo Liu, Lin Zhang, Zunmin Zhu
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 61 Issue 10 Pg. 2482-2487 (10 2020) ISSN: 1029-2403 [Electronic] United States
PMID32476519 (Publication Type: Journal Article)
Chemical References
  • HLA-DR Antigens
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
Topics
  • Adult
  • HLA-DR Antigens (genetics)
  • Humans
  • Leukemia, Myeloid, Acute
  • Leukemia, Promyelocytic, Acute (diagnosis, genetics)
  • Mutation
  • Prognosis
  • Retrospective Studies
  • fms-Like Tyrosine Kinase 3 (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: